Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uses of aloin as medicines for treating cerebral arterial thrombosis

A technology for ischemic stroke and ischemic stroke, which is applied in the field of aloin as a drug for treating ischemic stroke, can solve the problems that the protective effect has not been reported, and achieve the reduction of apoptosis rate and calcium ion Elevation of concentration, protective effect on ischemic injury

Active Publication Date: 2015-07-08
NINGXIA MEDICAL UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have found that aloin can help expel dirt from the body, purify blood, soften blood vessels, reduce blood pressure and blood viscosity, promote blood circulation, and prevent arteriosclerosis and cerebral hemorrhage. The protective effect of injury disease has not been reported so far, and its development as a drug for the treatment of ischemic stroke has extremely high potential value and social significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of aloin as medicines for treating cerebral arterial thrombosis
  • Uses of aloin as medicines for treating cerebral arterial thrombosis
  • Uses of aloin as medicines for treating cerebral arterial thrombosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] The purposes of aloin as medicine for the treatment of ischemic stroke, wherein, the molecular structural formula of aloin is as shown in formula (1)

[0022]

[0023] Ischemic stroke refers to ischemic stroke in the acute stage or repair stage. The single application dose of aloin in the cells is 10 μg / mL, and the dosage form of the drug is a powder injection dosage form allowed by pharmacy.

Embodiment 2

[0025] The use of aloin as a medicine for treating ischemic stroke, wherein the molecular structural formula of aloin is shown in formula (1)

[0026]

[0027] Ischemic stroke refers to ischemic stroke in the acute stage or repair stage, the single application dose of aloin in the cells is 20 μg / mL, and the dosage form of the drug is an injection dosage form allowed by pharmacy.

Embodiment 3

[0029] The use of aloin as a drug for the treatment of ischemic stroke, its molecular structural formula is shown in formula (1)

[0030]

[0031] The ischemic stroke is ischemic stroke in the acute phase or repairing phase, the single application dose of aloin in the cells is 40 μg / mL, and the dosage form of the drug is an oral dosage form permitted by pharmacy.

[0032] The effect of embodiment 1-3 can be verified by following animal experiments:

[0033] 1. Experimental materials

[0034] Cultured PC-12 cells, methazolium blue (MTT) was purchased from Guangzhou Chemical Reagent Factory; microplate reader was purchased from Thermo Company; lactate dehydrogenase LDH, malondialdehyde MDA, superoxide dismutase SOD, ROS assay Reagent kit: product of Nanjing Jiancheng Institute of Bioengineering; calcium ion, Hoechst, MMP kit: Biyuntian Reagent Company; Annexin V-FITC cell apoptosis detection kit: Shanghai Beibo Biological Company. Caspase-3, Bcl-2, Bax mRNA, internal refere...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Uses of aloin as medicines for treating cerebral arterial thrombosis are disclosed. By building an oxygen-glucose deprivation model, protective functions of the aloin for oxygen-glucose deprived PC-12 cells and possible mechanisms are researched. Experiment results show that: after oxygen-glucose deprivation reperfusion, the protective functions of the aloin are related to antioxidation, the aloin reduces contents of active oxygen and malonaldehyde in cells and increases the content of superoxide dismutase, the aloin can stabilize the mitochondrial membrane potential, and the aloin can reduce the apoptosis rate of the PC-12 cells and the concentration of calcium ions, and therefore the aloin is proved to have a protective function for ischemic injury.

Description

technical field [0001] The invention relates to the application of aloin, in particular to the application of aloin as a medicine for treating ischemic stroke. Background technique [0002] Ischemic Brain Disease (Ischemic Brain Disease), also known as ischemic stroke, has become one of the major fatal and disabling diseases worldwide, seriously threatening human life and health. Studies have found that after cerebral ischemia, a considerable part of the blood vessels can be recanalized naturally or after thrombolytic therapy, but it will lead to brain damage and dysfunction, that is, ischemia reperfusion injury (Ischemia Reperfusion Injury), thus inhibiting ischemia. Reperfusion injury has become a key link in the treatment of ischemic encephalopathy. [0003] Research on the mechanism of cerebral ischemia-reperfusion injury has progressed rapidly in recent years. Studies have found that brain cell damage caused by interruption of cerebral blood flow and reperfusion is a ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/351A61P9/10
Inventor 周茹常人元余建强郑婕赵启鹏张万年
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com